---
title: "Emcitate (tiratricol) in MCT8 deficiency: References"
description: "Reference list for the formulary evidence report on Emcitate (tiratricol) in MCT8 deficiency. 81 cited documents."
canonical: "https://www.evicenter.com/drugs/emcitate--mct8-deficiency/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Emcitate (tiratricol) in MCT8 deficiency: References

<a id="references"></a>

## 5 References

1. [Anderson et al. (2026)](https://www.gimopen.org/article/S2949-7744%2826%2900219-0/pdf)
2. [Bárez-López et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26701289/)
3. [Bauer et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11310894/)
4. [Becker et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38801167/)
5. [Boelaert et al. (2026)](https://academic.oup.com/jcem/article/111/4/911/8417742)
6. [Çelik et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39699593/)
7. [Chan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8824589/)
8. [Chen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9966820/)
9. [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)
10. [ClinicalTrials.gov NCT05579327](https://clinicaltrials.gov/study/NCT05579327)
11. [Costa et al. (2026)](https://novaresearch.unl.pt/en/publications/mct8-deficiency-three-patients-with-novel-slc16a2-mutations-at-di/)
12. [Dietrich et al. (2026)](https://doi.org/10.1159/000551857)
13. [Dubinski et al. (2025)](https://www.mdpi.com/2409-515X/11/3/66)
14. [Egetis Therapeutics approval announcement (2026)](https://www.egetis.com/news/egetis-therapeutics-announces-u-s-fda-approval-of-emcitate-tiratricol-for-patients-with-mct8-deficiency/)
15. [Egetis Therapeutics Breakthrough Therapy designation announcement (2025)](https://www.egetis.com/news/egetis-receives-fda-breakthrough-therapy-designation-for-tiratricol-for-mct8-deficiency/)
16. [Egetis Therapeutics Clinical Trials and Managed Access](https://www.egetis.com/healthcare-professionals/clinical-trials-managed-access/)
17. [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)
18. [Egetis Therapeutics EMCITATE prescription and enrollment form (2026)](https://www.emcitate.com/wp-content/themes/emcitate/assets/hcp_rx_enrollment_form.pdf)
19. [Egetis Therapeutics ETA and ESPE congress presentations announcement (2026)](https://attachment.news.eu.nasdaq.com/adb945672b400e6494d259f47116c7a1a)
20. [Egetis Therapeutics Fast Track designation announcement (2021)](https://www.egetis.com/news/egetis-therapeutics-receives-fda-fast-track-designation-for-emcitate-for-mct8-deficiency/)
21. [Egetis Therapeutics first quarter 2026 interim report (2026)](https://www.egetis.com/news/interim-report-q1-2026/)
22. [Egetis Therapeutics long-term efficacy and safety data announcement (2021)](https://www.egetis.com/news/new-data-confirms-long-term-efficacy-and-safety-of-emcitate-in-mct8-deficiency-patients/)
23. [Egetis Therapeutics NDA acceptance and priority review announcement (2026)](https://www.egetis.com/news/egetis-announces-fda-acceptance-and-priority-review-of-nda-for-emcitate-tiratricol-for-mct8-deficiency/)
24. [Egetis Therapeutics ReTRIACt results announcement (2025)](https://www.egetis.com/news/egetis-announces-positive-results-from-the-retriact-study-of-emcitate-tiratricol-in-mct8-deficiency/)
25. [Egetis Therapeutics rolling NDA review announcement (2025)](https://www.egetis.com/news/egetis-granted-a-rolling-nda-review-by-fda-for-emcitate-tiratricol-based-on-currently-available-clinical-data/)
26. [Egetis Therapeutics rolling NDA submission completion announcement (2026)](https://www.egetis.com/news/egetis-completes-the-u-s-rolling-nda-submission-for-emcitate-tiratricol-for-treatment-of-mct8-deficiency/)
27. [Egetis Therapeutics second quarter 2026 interim report (2026)](https://www.egetis.com/news/egetis-interim-report-q2-2026/)
28. [Egetis Therapeutics survival data announcement (2024)](https://www.egetis.com/news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/)
29. [Egetis Therapeutics Triac Trial II topline results announcement (2024)](https://www.egetis.com/news/egetis-announces-topline-results-of-the-phase-2-triac-trial-ii-with-emcitate-tiratricol-for-mct8-deficiency/)
30. [Egetis Therapeutics U.S. launch announcement (2026)](https://www.egetis.com/news/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2/)
31. [European Medicines Agency (2024)](https://www.ema.europa.eu/en/news/first-treatment-peripheral-thyrotoxicosis-patients-allan-herndon-dudley-syndrome)
32. [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)
33. [European Medicines Agency Emcitate EPAR](https://www.ema.europa.eu/en/medicines/human/EPAR/emcitate)
34. [European Medicines Agency Summary of Product Characteristics](https://www.ema.europa.eu/en/documents/product-information/emcitate-epar-product-information_en.pdf)
35. [FDA Emcitate approval announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency)
36. [FDA Novel Drug Approvals (2026)](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)
37. [FDA Orphan Drug Designations and Approvals (2019)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=666618)
38. [Freund et al. (2024a)](https://pure.eur.nl/en/publications/diagnosis-and-therapy-in-mct8-deficiency-ongoing-challenges/)
39. [Freund et al. (2024b)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBApuzKXgUtI5BZ-DdOMMKdRwzqjq-XL7Dq3vHEdWn0Na0)
40. [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)
41. [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)
42. [G-BA resolution on tiratricol (2025)](https://www.g-ba.de/downloads/39-1464-7475/2025-10-16_AM-RL-XII_Tiratricol_D-1191_EN.pdf)
43. [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)
44. [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)
45. [Groeneweg et al. (2020)](https://eprints.whiterose.ac.uk/id/eprint/180034/)
46. [Groeneweg et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11904026/)
47. [Groeneweg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12712983/)
48. [Haute Autorité de Santé Emcitate opinion page (2025)](https://www.has-sante.fr/jcms/p_3686952/en/emcitate-tiratricol-peripheral-thyrotoxicosis)
49. [Haute Autorité de Santé Transparency Committee summary opinion (2025)](https://www.has-sante.fr/upload/docs/application/pdf/2026-02/dir1/emcitate_100925_summary_ct21362.pdf)
50. [Investing.com Jefferies Global Healthcare Conference transcript (2026)](https://www.investing.com/news/transcripts/ani-pharmaceuticals-at-jefferies-rare-disease-growth-takes-center-stage-93CH-5032124)
51. [IQWiG (2025)](https://www.iqwig.de/en/projects/g25-17.html)
52. [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)
53. [Iwayama et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8558056/)
54. [Kersseboom et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5414784/)
55. [Kubota et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35945102/)
56. [Lamb (2025)](https://pubmed.ncbi.nlm.nih.gov/40549098/)
57. [Manders et al. (2026)](https://link.springer.com/article/10.1186/s13023-026-04269-7)
58. [McWalter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12182792/)
59. [National Organization for Rare Disorders (2025)](https://rarediseases.org/rare-diseases/mct8-specific-thyroid-hormone-cell-transporter-deficiency/)
60. [NCATS Global Substance Registration System](https://gsrs.ncats.nih.gov/ginas/app/ui/substances/b98c5197-201c-4099-81b5-6637269d82f4)
61. [Ofori et al. (2024a)](https://abstracts.eurospe.org/hrp/0098/hrp0098p2-372)
62. [Ofori et al. (2024b)](https://i0.wp.com/vitaccess.com/wp-content/uploads/2025/01/Ofori-et-al-2024-ISPOR-EU-2024-MCT8-deficiency-pdf-2025-01-1.png?resize=783%2C1121&ssl=1)
63. [Ofori et al. (2025)](https://vitaccess.com/publication/impact-of-caring-for-patients-with-monocarboxylate-transporter-8-mct8-deficiency-on-caregivers-sleep-results-from-an-international-cross-sectional-study/)
64. [Papademetriou et al. (2026)](https://www.ispor.org/docs/default-source/cti-meeting-21463-documents/2aa9006b-0f1e-473b-b624-79cf9a20602e.pdf?sfvrsn=285e5279_0)
65. [Persani et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11301568/)
66. [Pharmaphorum (2026)](https://pharmaphorum.com/news/us-mct8-deficiency-patients-get-1st-drug-emcitate-debuts)
67. [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)
68. [Pribilincová et al. (2025b)](https://www.sciencedirect.com/science/article/pii/S2214624525000218)
69. [Salas-Lucia et al. (2024)](https://insight.jci.org/articles/view/174645)
70. [Sarret et al. (2020)](https://www.ncbi.nlm.nih.gov/books/NBK26373/)
71. [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)
72. [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)
73. [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)
74. [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)
75. [van Geest et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735299/)
76. [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)
77. [Verge et al. (2012)](https://doi.org/10.1210/jc.2012-2556)
78. [Visser et al. (2016)](https://www.mct8.info/wp-content/uploads/2024/08/16_Visser-et-al-2016-Triiodothyroacetic-acid-treatment-in-MCT8-deficiency-a-word-of-nuance.pdf)
79. [Weiss et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11631802/)
80. [Wilpert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37881807/)
81. [Zung et al. (2024)](https://academic.oup.com/jcem/article/109/10/2589/7625621)

## Related pages
- [Emcitate (tiratricol): MCT8 deficiency](https://www.evicenter.com/drugs/emcitate--mct8-deficiency) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency.md)
- [Emcitate (tiratricol) in MCT8 deficiency: Terms and abbreviations](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/terms-and-abbreviations.md)
- [Emcitate (tiratricol): MCT8 deficiency](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/executive-summary) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/executive-summary.md)
- [Emcitate (tiratricol) in MCT8 deficiency: Product information and disease description](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/product-information-and-disease-description.md)
- [Emcitate (tiratricol) in MCT8 deficiency: Clinical evidence](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/clinical-evidence.md)
- [Emcitate (tiratricol) in MCT8 deficiency: Economic information and modeling report](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/economics) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/economics.md)
- [Emcitate (tiratricol) in MCT8 deficiency: new drug review](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/monograph/review) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/monograph/review.md)
- [Emcitate (tiratricol) in MCT8 deficiency: prevalence by geography](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/prevalence) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/prevalence.md)
- [Emcitate (tiratricol) in MCT8 deficiency: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/cost-effectiveness-analyses.md)
